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S U M M A R Y
Objective: To estimate the morbidity and mortality of pneumonia in adults over 50 years of age in
Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.
Methods: Local data sources were queried to estimate the number of hospitalized and outpatient
pneumonia cases and deaths in the year 2009. Pneumonia cases were identiﬁed in adults aged 50 years
using ICD-10 codes. The hospital case fatality rate (HCFR) by age corresponds to the percentage of
mortality per hospitalization.
Results: Cases of hospitalized pneumonia (incidence per 100 000 inhabitants/year) in adults 50 years
were: Argentina 39 674 (401.1); Brazil 225 341 (611.6); Chile 30 434 (738.5); Colombia 26 955 (326.6);
Mexico 82 397 (413.1); Venezuela 31 601 (640.1). The number of hospital deaths (CFR%) were: Argentina
5099 (13%); Brazil 47 287 (21%); Chile 3072 (10%); Colombia 2981 (11%); Mexico 13 312 (16%);
Venezuela 11 101 (35%). Cases of outpatient pneumonia (incidence per 100 000 inhabitants/year) were:
Argentina 54 093 (546.8); Brazil 260 277 (706.4); Chile 33 173 (804.9); Colombia 27 713 (335.8); Mexico
83 354 (417.9); Venezuela 39 645 (803.0). The percentage of episodes treated as outpatient was 64%
(range 57–80%) among those aged 50–64 years and 39% (range 8–56%) among those 85 years. Across
countries, 51% of hospitalizations (range 42–63%) and 69% of deaths (range 65–72%) were in adults 75
years.
Conclusions: Pneumonia is a common cause of hospitalization and mortality in adults in Latin America.
Incidence increases substantially with increasing age, as does the likelihood of hospitalization and
mortality.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Lower respiratory tract infections, including pneumonia, are
the third leading cause of death worldwide, responsible for an
estimated 3.8 million deaths in 2008.1 The incidence of pneumonia
is greatest among children aged 5 years and adults aged 50
years, with incidence increasing with each decade in adults over 50
years of age.2 Incidence is also increased in persons with chronic
disease, including chronic obstructive pulmonary disease (COPD),
kidney failure, congestive heart failure, coronary artery disease,
chronic neurological diseases, alcoholism, neoplastic diseases, and
immunosuppressive treatments.3–5
Among the elderly, the burden of pneumonia on healthcare
systems is likely to become more signiﬁcant over time given that* Corresponding author. Tel./Fax: +55 2976 1018.
E-mail address: gerado.luna@linksandlinks.com.mx (G.L. Casas).
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http://dx.doi.org/10.1016/j.ijid.2013.02.006the number of persons over the age of 60 years in the world will
triple, from 673 million in 2005 to two billion in 2050. This will be
most evident in developed countries, where it is estimated that this
age group will increase from 64% (2005) to 80% (2050) of the total
population,6 representing a signiﬁcant health problem throughout
the world, and an important clinical and economic burden due to
the signiﬁcant use of healthcare resources associated with each
case.7
It is estimated that approximately two million cases of
pneumonia are diagnosed each year in Argentina, Brazil, and
Chile.7 The mortality related to lower respiratory tract infections
(LRTIs) in Latin America is reported to be 6%, compared with 4% in
developed regions, and LRTIs were the third most frequent cause of
death in adults in 31 Latin American countries in 2001–2003.8,9 In
Brazil, case fatality rates (CFR) of hospitalized pneumonia increase
steadily with advancing age, with CFRs in adults 80 years of age
several fold higher than those of children 5–9 years, making it a top
cause of mortality.ses. Published by Elsevier Ltd. All rights reserved.
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and is the focus of many global and regional analyses.10–12
However, there is little reliable information on the speciﬁc
incidence and mortality of pneumonia in adults across Latin
America, despite recognition of the relative burden it places on
healthcare systems. Therefore, the objective of this study was to
estimate the morbidity and mortality burden of pneumonia in
adults over 50 years of age in Argentina, Brazil, Chile, Colombia,
Mexico, and Venezuela in 2009.
2. Methods
2.1. Description
A retrospective analysis of local data sources was conducted to
estimate the burden of pneumonia in Argentina, Brazil, Colombia,
Chile, Mexico, and Venezuela among adults. Data were stratiﬁed by
age groups of 50–64, 65–74, 75–84, and 85 years, to report the
incidence rates (inpatient and outpatient), the reported hospital
deaths, and the total annual burden of the disease in each country.
2.2. Data sources
To obtain pneumonia cases detected by the different healthcare
systems and in-hospital mortality information, speciﬁc databases
and queries of reported pneumonia cases were used in each
country, using as search criteria the cases reported in 2009 by ICD-
10 codes J12–J18, ICD-9 codes 480–486, gender, and age group.
Since pneumonia is a reportable disease in Mexico and in Latin
American countries, pneumonia cases were obtained from the
national epidemiological surveillance bulletins from week 1
through week 52 of the year 2009 for each country. In the case
of Brazil, the information was obtained from the Portal da Sau´de –
Secretariat of Health Surveillance;13 for Mexico, pneumonia cases
were obtained from the Epidemiological Bulletin Yearbook 2009 of
the National Epidemiological Surveillance Center;14 in the case of
Argentina, from the Health Ministry Epidemiological Bulletin 2009
for Acute Respiratory Diseases;15 for Chile, the information was
obtained from the epidemiological surveillance monthly electronic
bulletins of 2009 of the Department of Epidemiology, Ministry of
Health of Chile;16 for Venezuela the information was obtained
from the Epidemiological Bulletin 2009 of the Ministry of Popular
Power for Health;17 and ﬁnally in Colombia the information was
obtained through the 2009 Epidemiological Bulletin of the
National Institute of Health.18
Subsequently the following databases were consulted for each
speciﬁc country in order to obtain inpatient cases of pneumonia:
for Argentina the information was obtained from the Statistics and
Information Department of Health (DEIS),19 for Colombia the
information was provided by the National Institute of Health
(INS),20 for Mexico the information was available from the National
System of Health Information (SINAIS) and the National Epidemi-
ological Surveillance Center (CENEVACE),21,22 for Brazil reported
cases were obtained from the Database of the Uniﬁed HealthcareTable 1
Total pneumonia hospitalizations, deaths, and outpatient visits for adults over 50 year
Mexico Brazil 
Hospitalizations 82 397 225 341 
Outpatient visits 83 354 260 277 
Deaths 13 312 47 287 
Incidence rates (per 100 000)
Pneumonia hospitalizations 413.1 611.6 
Pneumonia outpatient visits 417.9 706.4 
Hospital case fatality rate (%) 16.2% 21.0% System (DATASUS),23,24 for Chile the cases were reported by the
Department of Statistics and Health Information of the Ministry of
Health of Chile (DEIS),25–28 and for Venezuela the statistical
database of the Ministry of Popular Power for Health (MPPS) was
consulted.29
To identify the total pneumonia cases treated as outpatients,
the difference between the cases reported by epidemiological
bulletins and the inpatient cases was determined, and the result
was considered as the cases that did not require hospitalization.
2.3. Incidence
The incidence was calculated based on the total cases of
pneumonia (ICD-10 codes J12–J18 and ICD-9 codes 480–486)
reported by the various local sources of epidemiological notiﬁca-
tion in each country during 2009,15–25 both for hospitalized
patients as well as non-hospitalized patients. Data were collected
within age groups (age 50–64, 65–74, 75–84, and 85 years),
which were then divided by the population  100 000 inhabitants,
respectively, to obtain the incidence rate per 100 000 person-years.
2.4. Mortality
The total numbers of deaths due to the ICD codes listed above
were obtained from data published by different local sources in
each country in regards to the reported deaths that required
hospital attention by age group (ages 50–64, 65–74, 75–84, and
85 years).19–29 Hospital deaths divided by the overall number of
hospitalizations were used to estimate a case fatality rate (percent
mortality per hospitalization) by age.
3. Results
In 2009, the total number of hospitalized cases (incidence per
100 000 inhabitants/year) for pneumonia in adults aged 50 years
in the various Latin American countries was: Mexico 82 397
(413.1); Brazil 225 341 (611.6); Colombia 26 955 (326.6);
Venezuela 31 601 (640.1); Chile 30 434 (738.5); and Argentina
39 674 (401.1) (Table 1). The incidence of hospitalized pneumonia
increased similarly in each country with each increasing age
category. Outpatient cases (incidence per 100 000 inhabitants/
year) of pneumonia in adults aged 50 years were: Mexico 83 354
(417.9); Brazil 260 277 (706.4); Colombia 27 713 (335.8);
Venezuela 39 645 (803.0); Chile 33 173 (804.9); and Argentina
54 093 (546.8). In general, the proportion of outpatient to inpatient
cases decreased with advancing age. In the age group 50–64 years,
the cases treated on an outpatient basis represented 64% (range
57–80%) of total cases, compared to the age group 85 years where
cases of outpatient care represented 39% (range 8–56%) of total
cases. The average death rate reported in 2009 for adults aged 50
years in the six countries studied was 17.7% (Table 2). The total
cases of hospital deaths reported (death rate, %) in each country
was as follows: Mexico 13 312 (16.2%); Brazil 47 287 (20.9%);
Colombia 2981 (11.0%); Venezuela 11 101 (35.1%); Chile 3072s of age, 2009
Colombia Venezuela Chile Argentina
26 955 31 601 30 434 39 674
27 713 39 645 33 173 54 093
2981 11 101 3072 5099
326.6 640.1 738.5 401.0
335.8 803.0 804.9 546.8
11.1% 35.1% 10.1% 12.9%
Table 2
Pneumonia inpatient and outpatient incidence and hospital case fatality rates by age, 2009
Country Age, years
50–64 65–74 75–84 85
Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient
Mexico
Cases 12 500 49 811 17 872 21 532 24 101 9679 27 924 2332
Incidencea 104.0 414.3 326.6 393.4 1304.0 523.7 4656.4 388.9
HCFR (%)b 12.4 12.6 16.5 19.8
Brazil
Cases 70 679 95 696 59 297 67 152 64 062 66 560 31 303 30 869
Incidencea 292.2 395.6 733.0 830.1 1700.9 1767.2 3922.9 3868.5
HCFR (%)b 10.2 13.6 30.2 40.4
Colombia
Cases 5701 11 320 5589 6924 8194 6108 7471 3361
Incidencea 102.2 203.0 325.2 402.9 1028.5 766.7 4636.3 2085.7
HCFR (%)b 6.9 9.5 12.7 13.6
Venezuela
Cases 6221 14 464 6767 9849 10 511 10 003 8102 5329
Incidencea 184.5 429.1 687.8 1001.1 2213.0 2106.0 7552.4 4967.5
HCFR (%)b 19.5 28.4 32.1 56.6
Chile
Cases 4965 12 235 6404 8756 10 635 7799 8430 4383
Incidencea 193.9 477.9 657.9 899.5 2252.9 1652.1 7295.5 3793.2
HCFR (%)b 7.7 8.6 9.4 13.6
Argentina
Cases 8814 11 588 8978 12 061 12 149 18 143 9734 12 301
Incidencea 159.9 210.2 367.4 493.6 849.5 1268.6 1916.0 2421.2
HCFR (%)b 8.4 12.0 13.2 17.2
a Incidence per 100 000 person years.
b Hospital case fatality rate (percent).
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in persons aged 75 years, who accounted for 69.2% (range 64.6–
72.0%) of total deaths in adults.
4. Discussion
Pneumonia is a frequent cause of physician visits, hospitaliza-
tion, and death among older adults in Latin America. Increasing age
was associated with a substantial increase in the overall incidence
of pneumonia, the likelihood of hospitalization, and the likelihood
of mortality. Among the studied population, 51% of hospitaliza-
tions (range 42–63%) and 69% of deaths (range 65–72%) were in
adults 75 years, who represented only 13% of the population
above 50 years of age.
Our ﬁndings are similar to other reports globally and regionally.
In Europe the incidence of hospitalized pneumonia in adults has
been reported with rates of 1.5–9.8 per 1000 population in persons
aged 65 years and older,30 which is lower than the 7.0–16.3 per
1000 persons aged 65 years and older across the countries in our
analysis. Our estimates are more aligned with an observational
study in Brazil, which reported the incidence of pneumonia from
2000 to 2007, resulting in an annual incidence in the age group 70–
79 years of 1134–1193 cases per 100 000 inhabitants, and in the
age group 80 years and over of 2177–2895 cases per 100 000
inhabitants.7
With regard to the hospital death rate, Caberlotto et al.
prospectively studied patients diagnosed with community-ac-
quired pneumonia (CAP) in two hospitals in Argentina and found
death rates of 13.5% and 13%, respectively,31 and the average age at
death was 58–68.31 years. In our study, the average death rate was
17.69% (10.10–35.11%) for adults aged 50 years, with a rate of
12.5% in Argentina. Jardim et al., carried out a multicenter clinical
study in ﬁve Latin American countries to evaluate the efﬁcacy and
safety of treatments with moxiﬂoxacin or amoxicillin in patients
18 years of age and older suspected of having CAP due to
pneumococcus; the study showed that the hospitalization rate ofthe patients studied was 52.8%.32 In our study, the average
hospitalization rate in the different Latin American countries for
adults aged 50 years was 46.7% (range 42.3–49.3%).
Hospitalized CAP may be caused by many organisms, with
Streptococcus pneumoniae (20–60%) being the most commonly
identiﬁed pathogen in Latin America.33,34,5 Vaccination of adults
against pneumococcal disease has the potential to reduce the
incidence of hospitalizations and associated costs of disease.35–38 A
23-valent polysaccharide vaccine (PPV23) is available in several
countries and is generally recommended for use in the elderly
based on its effectiveness in reducing invasive pneumococcal
disease.39 Guidelines for the use of PPV23 often recommend use in
adults over the ages of 50, 60, or 65 years, in recognition of their
heightened risk and the relative value of disease prevention.40 A
13-valent pneumococcal conjugate vaccine (PCV13) is now
approved in many countries for use in adults to prevent
pneumococcal disease caused by vaccine serotypes. A large clinical
trial is currently underway to investigate the efﬁcacy PCV13 in
reducing CAP in adults 65 years of age, which may further clarify
the potential role of this vaccine in clinical practice.41 Given the
high burden of pneumonia, the increase in morbidity and mortality
with increasing age, and the demographic aging of the population,
understanding the opportunity for disease prevention is of
increasing importance.
Pneumonia can impose signiﬁcant ﬁnancial costs due to
hospitalization, outpatient treatment, and lost productivity. In
this study we were limited to the identiﬁcation of pneumonia
cases through ICD-9 and ICD-10 registries, which are general
codes that often include unconﬁrmed cases, nosocomial pneu-
monias, readmissions, and hospitalizations due to other
causes.42–46 However, ICD-coded cases can be useful as a relative
metric to health utilization that can facilitate comparison within a
country, over time, in relation to other ICD-coded events, and
across demographic groups. Given this utility, studies have
applied ICD-based studies as a measure of pneumonia disease
burden in other parts of the world,47,48 and have evaluated
A.R. Buzzo et al. / International Journal of Infectious Diseases 17 (2013) e673–e677e676ICD-based pneumonia indicators over time as a metric for
monitoring pneumococcal vaccine impact.49–51
When ICD-coded all-cause hospitalized pneumonia data have
been compared against clinical records to identify radiographically
conﬁrmed CAP in adults, between 54% and 71% of coded cases meet
these criteria.42–46 Coding practices may vary by country and
region, and similar data are not currently available from Latin
American countries, therefore the transferability of these data is
uncertain. Further research into the validation of administrative
coded pneumonia cases in Latin America with regard to cause and
etiology would signiﬁcantly beneﬁt our understanding of the
nature of pneumonia in adults.
In conclusion, we found a population weighted average
incidence of hospitalized pneumonia in persons over 50 years of
age of 519.6 hospitalizations per 100 000 person years, with an
average fatality rate of 19.0 per 100 hospitalizations, representing
436 402 hospitalizations and 82 852 deaths in 2009. Assuming the
same disease behavior for the 1.03 billion population over 50
across Latin American countries,52 this represents an estimated
533 083 hospitalizations and 101 283 deaths per year. Extrapolat-
ing forward to 2020, with a projected adult population of 1.49
billion, pneumonia could account for up to 617 993 hospitaliza-
tions and 112 680 deaths in a single year. Pneumonia represents a
signiﬁcant health burden in adults, which may continue to grow as
the population ages.
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